INFUSE® Bone Graft/LT-CAGE® Lumbar Tapered Fusion Device - INFUSE® Bone Graft is a revolutionary technology which can be used to eliminate the need for an autogenous bone graft to be harvested from the patient's hip.
Studied under extensive clinical trials, INFUSE® Bone Graft and the LT-CAGE® Device consistently achieved rates of fusion and recovery equivalent to autograft. And because it contains the only bone morphogenetic protein approved for spinal fusion, INFUSE® Bone Graft/LT-CAGE® Device requires no autograft.
If you have any questions or need additional information about INFUSE® Bone Graft, you can visit www.infusebonegraft.com or talk to a doctor, who is the only one qualified to diagnose and treat your condition. As with any surgical procedure, you should find a doctor who is experienced in performing the specific surgery that you are considering.
rhBMP-2
Recombinant human bone morphogenetic protein (rhBMP) has long been recognized for its potential as a bone graft substitute. In fact, BMPs are the only known proteins capable of inducing new bone formation. And the first commercially available BMP ever to exhibit clinically proven osteoinductivity is the INFUSE® Bone Graft/LT-CAGE® device.
Testing INFUSE® Bone Graft with the LT-CAGE® Device
Capping years of promising performance in preclinical studies, INFUSE® Bone Graft and the LT-CAGE® Device were tested in the most rigorous manner possible, in a prospective randomized large-scale clinical trial using an open surgical approach. Involving 279 patients and 16 investigative sites, the trial achieved its initial goal-proving that INFUSE® Bone Graft and the LT-CAGE® Device were just as effective as autogenous bone graft.
Other advantages surfaced as well. The INFUSE® Bone Graft/LT-CAGE® Device group lost significantly less blood than autograft recipients. Operating times were shorter. And most notably, though statistically equivalent, rates of fusion were 94.5% in the INFUSE® Bone Graft/LT-CAGE® Device group and 88.7% in the autograft group at 24 months.
The Study
- Multicentered, prospective, randomized, 2-year trial.
- Patient breakdown: 136 autograft/LT-CAGE® Device, 143 INFUSE® Bone Graft/LT-CAGE® Device
Subjects had single-level, symptomatic degenerative disc disease.
The Findings
- INFUSE® Bone Graft/LT-CAGE® Device was found safe.
- INFUSE® Bone Graft/LT-CAGE® Device patients showed a slightly higher though statistically equivalent average fusion rate than autograft control group.
- From CT reconstructions, INFUSE® Bone Graft/LT-CAGE® Device patients exhibited new bone growth.
- Operating times and blood loss were reduced for INFUSE® Bone Graft/LT-CAGE® Device open patients as compared to control patients.
- INFUSE® Bone Graft/LT-CAGE® Device eliminated pain and complications relating to bone harvest.
- All new bone growth was within the margins of the disc space.
If you are anticipating spine surgery, ask your doctor if you are a potential candidate for INFUSE® Bone Graft/LT-CAGE® Device.
Click here to print out a letter for your physician. Find out if you are a candidate for INFUSE® Bone Graft/LT-CAGE® Device.
Click here to find a doctor who has attended training on INFUSE® Bone Graft/LT-CAGE® Lumbar Tapered Fusion Device.
CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician with appropriate training or experience.
 Important Safety Information
|
